Advancing Aminoadamantane-based Therapeutics for CNS Disorders

Adamas Pharmaceuticals is a leading developer of aminoadamantane-based therapeutics. The Company’s products are designed to be better tolerated, more effective and easier-to-use formulations. The three lead product candidates include MDX-8704 and ADS-8704, the first potential fixed dose combination drug treatment for Alzheimer’s disease, and Nurelin™ (ADS-5102) the first potential drug labeled for the treatment of Levodopa-induced dyskinesia in Parkinson’s disease.